Yale School of Medicine
Department of Immunobiology

Carla Rothlin, Ph.D.
Dorys McConnell Duberg Professor of Immunobiology
and Pharmacology

300 Cedar Street
TAC S625A
P.O. Box 208011
New Haven, CT 06520-8011
Telephone: (203) 737-4679
Fax: (203) 785-4972
E-mail: carla.rothlin@yale.edu

March 23rd, 2025

Re: Nomination, International Union of Immunological Societies (IUIS)

Dear Secretary General,

I am honored to submit my self-nomination for the position of Vice President of IUIS. As an immunologist dedicated to advancing our field on a global scale, I am deeply committed to fostering scientific excellence, international collaboration, and equitable access to immunological knowledge. Through my leadership and over two decades of experience in immunology, I believe I am well positioned to contribute meaningfully to the mission of IUIS.

Throughout my career, I have demonstrated scientific leadership through groundbreaking research in immune regulation, particularly on the response to cell death and the negative regulation of inflammation. I am the Dorys McConnell Duberg Professor of Immunobiology and Pharmacology at Yale University, where I lead a productive research program that has expanded our understanding of innate immune regulation, macrophage and dendritic cell biology, and tissue immunity. Our discoveries have been recognized through numerous high-impact publications in journals such as *Science*, *Cell*, *Nature*, *Immunity* and *eLife*. I have also been invited to present at premier international conferences, including those organized by AAI where I was a Distinguished Lecturer, Keystone Symposia as well as IUIS congresses and courses.

In addition to my scientific contributions, I have launched large-scale international initiatives aimed at democratizing access to knowledge in immunology. As the co-founder of the Global Immunotalks, I have helped establish a virtual seminar series that reaches thousands of immunologists across the world, providing free access to cutting-edge research and thought leadership. The success of this initiative, with over 150,000 views on our YouTube Channel per year, underscores my commitment to expanding access to scientific knowledge beyond traditional academic institutions. Furthermore, I launched the Global Immunocourse, an in-person educational initiative designed to bring foundational immunology training to regions with limited access to advanced education. The course has been held twice in India, the inaugural one in 2023 at the Indian Institute of Science and the second one in 2024 at Ashoka University. We are currently working to expand to additional locations in the global south.

My leadership roles extend beyond my own initiatives. I have served or currently serve as an

organizer and advisory board member for numerous international scientific meetings, including Keystone Symposia and EMBO conferences. I hold editorial and advisory roles at leading immunology journals. I was a Senior Editor of *eLife* for five years and contributed to ensuring the highest standards of scientific rigor and integrity in research publications.

IUIS's mission to promote immunology worldwide aligns perfectly with my vision of fostering international collaboration and ensuring access to education and the latest discoveries in immunology. I believe that my experience in spearheading global initiatives, combined with my leadership in academia and research, positions me well to contribute effectively as Vice President of IUIS. I sincerely appreciate your consideration of my candidacy and welcome the opportunity to further discuss how my experience and vision align with the objectives of IUIS.

Sincerely,



Carla V Rothlin, Ph.D.
Dorys McConnell Duberg Professor
Yale School of Medicine

CURRICULUM VITAE

Name: Carla V. Rothlin, Ph.D.

Education:

Biochemist	University of Buenos Aires	1996
Pharmacist	University of Buenos Aires	2002
Ph.D.	University of Buenos Aires	2002

Career/Academic Positions:

01/1998 – 07/2002	Graduate Student, INGEBI, Argentina
03/1998 – 07/1998	Visiting Student, Molecular Neurobiology Laboratory The Salk Institute for Biological Studies, USA
08/2002 – 08/2004	Pew Latin American Fellow The Salk Institute for Biological Studies, USA
09/2004 – 06/2008	Research Associate The Salk Institute for Biological Studies, USA
07/2008 – 07/2009	Staff Scientist, The Salk Institute for Biological Studies, USA
08/2009 – 06/2015	Assistant Professor, Department of Immunobiology, Yale University, School of Medicine
07/2015 – 06/2017	Associate Professor, Department of Immunobiology, Yale University, School of Medicine
07/2015 – 06/2019	Associate Professor, Department of Pharmacology, Yale University, School of Medicine
07/2017 – 06/2019	Associate Professor (Tenured), Department of Immunobiology, Yale University, School of Medicine
11/2016 – 11/2021	HHMI Faculty Scholar
07/2019 – present	Dorys McConnell Duberg Professor of Immunobiology and Pharmacology, Department of Immunobiology, School of Medicine, Yale University

Administrative Positions:

2019-present	Co-leader, Cancer Immunology Program, Yale Cancer Center.
2019-present	Co-program Director, Yale Interdisciplinary Immunobiology Training Program
2018-present	Director of Graduate Studies, Department of Immunobiology.
2019-present	Member of the Executive Committee of the Department of Immunobiology.
2012-2017	Course Director, Introduction to Immunology, course MCDB 430/IBIO 530.

Professional Memberships:

2008-present	American Association of Immunologists
2014-present	The Henry Kunkel Society
2019-present	International Cytokine and Interferon Society

Honors:

National:

2025	Elected to the Connecticut Academy of Science and Engineering
2023	Distinguished Lecturer, AAI
2019	Dorys McConnell Duberg Professor of Immunobiology and Pharmacology
2019	One of 25 investigators selected for commenting on the future of immunology for Immunity's 25th year edition
2016	HHMI Faculty Scholar
2014	Elected as a member of the Henry Kunkel Society

2011 Early Excellence Award, American Asthma Foundation
2010 Senior Research Award, Crohn's and Colitis Foundation of America
2008 American Heart Association National Center, Scientist Developmental Award
2008 Leukemia and Lymphoma Society, Special Fellow, Career Developmental Award
2002-2004 Pew Latin American Fellowship, Pew Charitable Trusts
2001 International Brain Research Organization (IBRO) Travel Award. Society for Neuroscience

International:

2023 Satish Dhawan Visiting Professor, Indian Institute of Science, Bangalore, India
2000 Bernardo A. Houssay Award, Argentine Society of Biology, "Cloning and Functional Characterization of the Nicotinic Receptor Involved In the Vestibular and Cochlear Efferent Control." Rothlin C V, Katz E, Elgoyhen A B.
1998–2002 Doctoral Fellowship, National Research Council (CONICET), Argentina

Keynote and Named Lectures

2024 Keynote Speaker, Microbiology and Immunology Retreat, University of Utah Health, Utah.
2024 Keynote Speaker, Brown Pathology Retreat, Brown University, Providence, Rhode Island.
2023 Distinguished Lecture, AAI.
2022 Dr. Anton Bennet and Dr. Titilayo Omotade Distinguished Lecture, 2022 Yale Biological and Biomedical Sciences Diversity and Inclusion Collective Research Symposium.
2018 Keynote Speaker, MSKCC retreat, Mohonk Mountain, NY.
2017 Keynote Speaker. Dutch Society of Immunology, Annual Meeting, Netherlands.
2017 Susan Swerling Lecture, Dana Farber Cancer Institute, Boston, USA.
2017 Keynote Speaker, Immunology Retreat, Harvard Immunology Program.
2014 Keynote Speaker, Annual Retreat, Immunology Program, Washington University, St Louis, Missouri.

Grant History:

A. Active

Agency: NIH/NIA, 1RF1AG082190
Title: Augmenting AXL and MERTK function to restrain cognitive decline and improve health span in mouse models of Alzheimer's Disease
PI: Rothlin (contact), Ghosh, Grutzendler, Horvath
Project period: 04/01/2023 - 03/31/2026

Agency: NIH/NEI, R01EY034003
Title: Inflammation in MERTK-dependent Retinitis Pigmentosa
PI: Rothlin (contact), Ghosh, Finnemann
Project period: 09/01/2023 - 01/31/2028

Agency: NIH/NIAID, R21AI174387
Title: Naïve T cell archetypes and anti-tumor immunity
PI: Rothlin (contact), Ghosh
Project period: 07/01/2023 - 06/31/2025

Agency: NIH/NIAMS 2R01AR070313-06
Title: "Deciphering how tissue resident macrophages regulate musculoskeletal regeneration in spiny mice"
P.I.: Seifert
Co-I: Rothlin and Ghosh
Project period: 07/01/2024 – 06/30/2029

Agency: DoD; CA210204
Title: "Inflammation and CRC: Necroptosis and Fibroblasts Tip the Balance"

PI: Rothlin
Project period: 09/01/2022 - 08/31/2025

Agency: Bright Focus
Title: Functional understanding of AXL effector role(s) in microglia towards developing disease modifying therapies in Alzheimer's Disease
PI: Rothlin (contact), Ghosh
Project period: 07/01/2023 - 06/30/2026

Agency: Fighting Blindness
Title: A novel, rationally designed pharmacological approach to countering vision loss in a preclinical model of MERTK-associated Retinitis Pigmentosa
PI: Finnemann (contact), Rothlin, Ghosh
Project period: 09/01/2023 – 08/31/2028

Agency: NIH/NIAID 5T32AI007019-47
Title: "Interdisciplinary Immunology Training Program"
P.I.: Schatz and Rothlin
Project period: 09/01/2022 - 08/31/2027

Agency: Mirati Therapeutics
Title: "Phase 2 Trial of Sitravatinib plus Pembrolizumab in Patients with Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer"
P.I.: Goldberg
Role: Rothlin and Ghosh, PIs Correlatives
Project period: 04/01/2022 – 03/31/2025

Agency: NIH/NIBIB; 1R01EB031821-01
Title: "Development of novel human Fab probes for PET imaging of macrophages"
PI: Marquez-Nostra
Role: Rothlin, Co-investigator
Project period: 08/15/2021 - 07/31/2025

Agency: NIH/NCI; 1R01CA262377-01
Title: "Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer"
PI: Schalper
Role: Rothlin, Co-investigator
Project period: 09/10/2021 - 08/31/2026

Agency: NIH/NCI; 2P50CA121974-11A1
Yale SPORE in Skin Cancer
Title: Project 4: Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade
PI: Bosenberg
Project period: 09/01/2018-08/31/2023

Agency: NIH/NCI; P30CA016359
Cancer Center Support Grant
PI: Winer
Project period: 09/01/2019-07/31/2029

Agency: Novartis Institute for Biomedical Research
Title: Early detection of cellular perturbations in microglia and astrocytes linked to functional disruption of brain networks in Alzheimer's Disease

PI: Cardin
Co-PI: Rothlin
Project period: 01/01/2024 - 12/31/2027

B. Past

Agency: CRI; CRI4388 *Wade F.B. Thompson CLIP grant*
Title: "Microbiome effect on naïve T cell transcriptional heterogeneity and anti-tumor immunity"
PI: Rothlin
Project period: 07/01/2022 - 06/30/2024

Agency: NIH/NIA; 1R56AG074015-01
Title: "Sex-Specific Single Cell Expression Profiles, Genetic Risk and Drug Responsiveness in Alzheimer's Disease"
PI: Strittmatter (contact), Rothlin, Ghosh, Zhang, Zhao
Project period: 09/15/2021 - 05/31/2024

Agency: NIH/NIA 3R01CA212376-01A1S
Title: "An innate immune checkpoint in cancer immunotherapy"
FOA: PA18-591, Supplement application related to: Cancer- and cancer treatment-related neurocognitive function.
P.I.: Rothlin and Ghosh
Project period: 03/01/2021 – 02/28/2023

Agency: NIH/NCI 1R01CA212376
Title: "An innate immune checkpoint in cancer immunotherapy"
P.I.: Rothlin and Ghosh
Project period: 03/01/2017 – 02/28/2023

Agency: NIH/NCI; 1R01CA216846
Title: "Renalase inhibition for treatment of unresectable melanoma"
PI: Kluger
Role: Rothlin, Co-investigator
Project period: 04/01/2017 – 03/31/2023

Agency: Ludwig Family Foundation
Title: "Alzheimer's Disease Immunology"
PI: Rothlin and Ghosh
Project period: 12/04/2019-12/03/2022

Agency: HHMI
Title: HHMI Faculty Scholar
P.I.: Rothlin
Project period: 11/01/2016-30/10/2022

Agency: Kenneth Rainin Foundation
Title: "Death begets a new beginning"
PI: Rothlin
Project period: 10/01/2018-03/31/2023

Agency: Yale SPORE in Lung Cancer (YSILC) developmental award
Title: "Target validation and proof-of-concept for MERTK inhibition in preclinical models of lung cancer"
PI: Rothlin and Ghosh
Project period: 08/01/2020 - 07/31/2021

Agency: NIH/NIAID 1R01 AI121183
Title: "Mechanisms regulating fetal membrane and neutrophil responses to polymicrobial infection"
PI: Abrahams
Role: Rothlin, Co-investigator
Project period: 06/25/2016 - 05/31/2021

Agency: NIH/NINDS; 1 R01 NS095993
Title: "Efferocytosis and the resolution of inflammation after intracerebral hemorrhage"
PI: Sansing
Role: Rothlin, Co-investigator
Project period: 09/01/2016 – 08/31/2021

Agency: NIH/NIAID R01 AI 089824
Title: "TAM receptor tyrosine kinases in inflammatory bowel disease"
P.I.: Rothlin
Project period: 09/01/2010-08/31/2021

Agency: Roche Translational and Clinical Research Center, Inc.
Title: "Deciphering TAM RTK biology"
PI: Rothlin
Project period: 08/08/2017-08/07/2021

Agency: Yale Cancer Center
Title: "Overcoming barriers for effective brain tumor immunotherapy"
PI: Rothlin and Ghosh
Project period: 09/01/2018-08/31/2020

Agency: United States-Israel Binational Science Foundation
Title: "Regulation of oral mucosa homeostasis by Gas6"
P.I.: Rothlin, Co-PI
Project period: 07/01/2016 - 06/30/2020

Agency: Kolltan Pharmaceuticals
Title: Specificity of TAM RTK immune function
PI: Rothlin
Project period: 01/01/2015 – 12/31/2018

Agency: NIH/NIA; Yale's Alzheimer's Disease Research Center Pilot Grant
Title: "Mechanisms of reactive astrogliosis – a critical feature in Alzheimer's Disease"
PI: Rothlin
Project period: 09/01/2017 – 08/31/2018

Agency: Alliance for Lupus Research
Title: "Protein S: at the crossroads of thrombosis and inflammation in SLE"
P.I.: Rothlin
Project period: 02/02/2015 - 01/31/2018

Agency: Yale Skin Spore developmental research award
Title: "An emerging new target in cancer immunotherapy"
P.I.: Rothlin
Project period: 09/15/2014 - 09/14/2016

Agency: AbbVie-Yale
Title: "Thrombosis in IBD: causal or coincidental"
P.I.: Rothlin
Project period: 07/1/2014-06/30/2016

Agency: Yale Cancer Center Pilot Program
Title: TAMing inflammation associated cancer
P.I.: Rothlin
Project period: 04/01/2013 - 03/31/2014

Agency: American Asthma Foundation M0148282
Title: "The TAM tyrosine kinase signaling pathway prevents allergic airway hyper-responsiveness"
P.I.: Rothlin
Project period: 07/01/11-06/30/14

Agency: Lupus Research Institute
Title: "TAMing the pathogenic Type I Interferon response in SLE"
P.I.: Rothlin
Project period: 02/01/2011-01/31/2014

Agency: Crohn's & Colitis Foundation of America
Title: "Role of TAM receptor signaling in intestinal mucosal homeostasis"
P.I.: Rothlin
Project period: 01/01/2010-12/31/2013

Agency: American Heart Association
Title: "Molecular Determinants of TAM mediated inhibition of the immune response and the development of atherosclerosis"
P.I.: Rothlin
Project period: 07/01/2008-06/30/2013

Agency: American Heart Association (AHA), Western States Affiliate
P.I.: Rothlin
Declined, in favor of AHA National

Agency: Leukemia and Lymphoma Society, Career Development Award
P.I.: Rothlin
Declined, in favor of AHA National

Invited Talks:

2025 Distinguished Speaker, Pelotonia Institute for Immuno-Oncology, Ohio State University, USA
2025 Carter Immunology Center, University of Virginia, USA
2025 Seminários do Programa de Bioquímica e Biologia Celular e Molecular, Universidade de São Paulo, Riberão Preto, Brazil.
2024 Keystone Symposia, "Fibrosis: Inflammation, Drivers, and Therapeutic Resolution", Whistler, Canada.
2024 Pathology Seminar Series Michael Bennett, M.D., Lecture in Immunopathology, UT Southwestern, USA.
2024 ALACI (Association of Latin American and Caribbean Association of Immunology), Buenos Aires, Argentina.
2024 Immunocon, Indian Immunology Society meeting, Bangalore, India.
2024 Brazilian Immunology Society, Fortaleza, Brazil.

2024 Keynote Speaker, Microbiology and Immunology Retreat, University of Utah Health, Utah.
2024 Keynote Speaker, Brown Pathology Retreat, Brown University, Providence, Rhode Island.
2024 Danny Thomas Lecture, St Jude Children's Hospital, Memphis, Tennessee, USA.
2024 19th International Aegean Innate Immunity Conference, Corintio, Greece.
2024 Keystone symposia, "Myeloid targeting strategies for Cancer Treatment", Killarney, Ireland.
2024 Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, USA.
2024 Department of Pharmacology, UCSD, San Diego, USA.
2024 Keystone symposia, "Regulation of Barrier Immunity", Banff, Canada.
2024 Keystone symposia, "Inhibitory receptors in immune homeostasis, disease and therapy", Breckenridge, Colorado
2023 IUIS International immunology congress, Cape Town, South Africa
2023 European Macrophage and Dendritic Cell Society Meeting, Gent, Belgium
2023 Australian Society of Immunology visiting speaker – presented at
Garvan Institute (Sydney)
Centenary Institute (Sydney)
QIMRB (Brisbane)
Frazer Institute (Brisbane)
Monash University (Melbourne)
Peter MacCallum (Melbourne).
2023 IBioBA, Buenos Aires, Argentina
2023 Academia Nacional de Medicina, Buenos Aires, Argentina
2023 Ingebi, Buenos Aires, Argentina
2023 FASEB Autoimmunity Conference, Southbridge, Massachusetts, USA
2023 Cell Symposia on Myeloid Cells, Shanghai, China
2023 Institute of Translational Medicine (ITM), Zhejiang University, China
2023 IMCB, Singapore, Singapore
2023 Department of Zoology, Kolkata University, Kolkata, India
2023 Indian Institute of Chemical Biology, Kolkata, India
2023 InStem, Bengaluru, India
2023 Indian Institute of Science, Bengaluru, India
2023 National Institute of Immunology, Delhi, India
2023 Department of Microbiology, Immunology & Molecular Genetics, UT Health San Antonio, Texas, USA
2023 CNIC, Madrid, Spain
2022 Genentech, South San Francisco, California, USA
2022 Ribble Seminar Series, University of Kentucky, Lexington, Kentucky, USA.
2022 10th Annual meeting of the International Cytokine and Interferon Society, Hawaii, USA.
2022 "Phagocytosis of dying cells: Molecules, mechanisms, and therapeutic implications", EMBO Conference, Ghent, Belgium
2022 FASEB meeting, Molecular Mechanisms of Immune Cell Development and Function, Nova Scotia, Canada
2022 Keystone meeting, Resolution of Inflammation, Keystone Colorado
2022 Gordon Conference, Immunohistochemistry and Immunobiology, Barcelona, Spain
2022 Montreal Clinical Research Institute, Montreal, Canada
2022 Immunology and Microbiology Program, University of MASS Chan, Massachusetts
2022 Gordon Conference, Cell Death, Les Diablerets, Switzerland
2022 The Salk Institute, La Jolla, California
2022 Center for Immunology, University of Minnesota, Minnesota
2022 Immunology Program, UCSF, California.
2022 Immunology Program, Harvard, Massachusetts.
2022 Cardiff University Science Seminar, UK.
2021 Department of Microbiology and Immunology, Stanford University School of Medicine (virtual)
2021 Center for Virus Research, University of California, Irvine (virtual)
2021 Department of Physiology, McGill, Montreal, Canada (virtual)

2021 Department of Microbiology and Immunology, University of Kentucky, Lexington (virtual).
2021 Center for Inflammation, Infection and Immunity. Hamburg-Eppendorf University, Hamburg, Germany (virtual)
2020 Precision Immunology Institute, Mount Sinai, New York (virtual).
2020 Division of Immunobiology, Washington University St Louis, Missouri (virtual).
2020 NextGen 2020, Rehobot, Israel.
2020 Immunology Department, Columbia University, New York.
2019 Immunology Seminar Series, Duke University, North Carolina.
2019 Tri-Institutional Immunology and Microbial Pathogenesis Program Research Seminar Series, Sloan Kettering, New York.
2019 NHRI/IBMS Joint International Conference on Inflammation & Disease, Taipei, Taiwan
2019 Grand Challenges in Immunology: Immunotherapy for Cancer and Beyond. Nature Conference, Qingdao, China.
2019 The Autoimmunity Faseb Conference, Asilomar, California
2019 Immune Cells at the Forefront of Health and Disease, i3D symposium, Rutgers University, Newark, New Jersey.
2019 13th International Congress on SLE, San Francisco, California.
2019 Immunology Seminar Series, UC Berkeley, California.
2019 Keystone Symposium, Innate and Non-Classical Immune Cells in Cancer Immunotherapy, Keystone, Colorado.
2019 1st Symposium on Immunometabolism of Yale University and Shanghai Jiao Tong University School of Medicine, Shanghai, China
2019 Keystone Symposium, Innate Immune Receptors: Roles in Immunology and Beyond, Taipei, Taiwan
2019 Keystone Symposium, Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity, Breckenridge, Colorado.
2019 Center for Immunology Seminar Series, University of Minnesota, Minnesota.
2019 Thomas E. Starzl Transplantation Institute Seminar Series, University of Pittsburgh, Pennsylvania.
2018 Department of Immunology Seminar Series, MD Anderson, Houston, Texas.
2018 Cytokines 2018, Boston, Massachusetts, USA.
2018 “Phagocytosis of dying cells: Molecules, mechanisms, and therapeutic implications”, EMBO Conference, Ghent, Belgium
2018 Yale Severe Asthma Symposium, New Haven, CT, USA.
2018 44th New England Immunology Conference, MBL, Massachusetts, USA.
2018 XLIII Congress of the Brazilian Society of Immunology, Ouro Preto, Brazil.
2018 Gordon Conference, Tissue Niches and Resident Stem Cells in Adult Epithelia, New Hampshire, USA
2018 Shanghai Institute of Immunology, Immunology Summer School, Shanghai, China
2018 USTC, Hefei, China
2018 European Society of Clinical Investigation, Phagocyte Symposium, Barcelona, Spain
2018 Department of Immunology Seminar Series, University of Washington, Seattle, USA.
2018 Committee in Immunology Seminar Series, University of Chicago, USA.
2018 Department of Immunology Seminar Series, University of Massachusetts, Worcester, USA.
2018 Keynote Speaker, MSKCC retreat, Mohonk Mountain, NY.
2018 American Association of Immunologists Annual Meeting. May 4-8, Austin, Texas, USA.
2018 NIH Immunology Interest Group Seminar Series, Bethesda, Washington.
2018 57th Midwinter Conference of Immunologists, Asilomar, CA.
2018 Keystone symposium, The Resolution of Inflammation in Health and Disease, Dublin, Ireland.
2018 IUIS-FAIS-SMI-Immuno-Morocco Course, Fes, Morocco.
2017 French Dendritic Cell Society Meeting, Paris, France.
2017 Keynote Speaker. Dutch Society of Immunology, Annual Meeting, Netherlands.
2017 Keystone symposium, Mononuclear Phagocytes in Health, Immune Defense and Disease, Austin Texas, USA.

2017 UCSF Immunology Program Seminar Series, UCSF, USA.
2017 Department of Pharmacology Seminar Series, UCSD, USA.
2017 Susan Swerling Lecture, Dana Farber Cancer Institute, Boston, USA.
2017 Society for Leukocyte Biology Meeting, Vancouver, Canada.
2017 FASEB meeting on Molecular Mechanisms of Lymphocyte Development and Function, Snow Mass Village, Colorado, USA.
2017 Society for Immunotherapy of Cancer (SITC), Guest Society symposium, Annual Meeting of the American Association of Immunologists (AAI), Washington DC, USA.
2017 International Congress of Mucosal Immunology, Washington DC, USA.
2017 Keynote Speaker, Immunology Retreat, Harvard Immunology Program
2017 Harvard Medical School, Immunology Seminar Series, Boston, USA.
2017 Keystone symposium, Immune Regulation in Autoimmunity and Cancer, Whistler, British Columbia, Canada.
2017 Dana Farber Cancer Institute Cancer Immunology Seminar Series, Boston, USA.
2017 Keystone symposium, Cell Plasticity within the Tumor Microenvironment, Big Sky, Montana, USA.
2017 Keystone symposium, Asthma: From Pathway Biology to Precision Therapeutics, Keystone, Colorado, USA.
2016 SAFE (Argentinian Society of Pharmacology) Annual Meeting, Mar del Plata, Argentina. "Resolution of Inflammation".
2016 SBBC 2016 - XVIII Congress of the Brazilian Society for Cell Biology, Sao Paulo, Brazil. "Resolution of Inflammation".
2016 Human Translational Immunology (HTI) Seminar Series, Yale University. "Regulation of Type II I mmune response".
2016 Cancer Immunology Seminar Series, Cancer Center, Yale University. "An eMERging target in cancer immunotherapy".
2016 NIH Twinbrook Seminar Series, Bethesda, Maryland. "Negative regulation of the immune response".
2016 Keystone symposium, Myeloid Cells, Killarney, Ireland. "TAM receptors in Immunity".
2015 Cell Symposium, Cell Death and Immunity. "A new perspective on resolution of inflammation". Berkeley, CA, USA.
2015 Annual Symposium, 12th World Congress of Inflammation, Boston, Massachusetts. "TAM receptor tyrosine kinases regulate the magnitude of the Immune Response".
2015 Annual Symposium, Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts. "TAM signaling in the resolution of Inflammation".
2015 Gordon Conference, Apoptotic Cell Recognition & Clearance, University of New England, Maine. "TAM receptor tyrosine kinase signaling in the resolution of Inflammation".
2015 Seminar Series, Rigel Pharmaceuticals, South San Francisco, California. "Immunobiology of TAM receptor tyrosine kinases".
2015 Annual Meeting of the Henry Kunkel Society, Annecy, France. "Negative regulation of Type II Immunity".
2015 Department of Pathobiology Seminar Series, University of Pennsylvania. "MeTAMophosis of Protein S".
2015 Vascular Biology and Therapeutics Program and Section of Cardiovascular Medicine Seminar series, Yale University. "MeTAMophosis of the anticoagulant protein Protein S".
2015 Keystone symposium, Autoimmunity ad Tolerance, Keystone, Colorado. "TAM Kinases Regulate the Magnitude of Innate and Adaptative Responses in Mice".
2014 Keynote Speaker, Annual Retreat, Immunology Program, Washington University, St Louis, Missouri. "MeTAMorphosis of Protein S".
2014 Kolltan Pharmaceuticals, New Haven, Connecticut. "TAM RTK signaling in immune function: translating basic findings into new therapies".
2014 Division of Respiratory, Inflammation and Autoimmunity, MedImmune, Washington, DC. "MeTAMorphosis of Protein S".
2014 Immunology Seminar Series, Memorial Sloan Kettering Cancer Center, New York City, New York. "MeTAMorphosis of Protein S".

2014 Keystone symposium, Innate Immunity to viral infections, Keystone, Colorado. “Negative regulation of Type I IFNs”.
2014 Microbiology, Immunology and Cancer Biology seminar series, University of Virginia, Charlottesville, VA. “Immunobiology of TAM receptors”
2013 Mayo Clinic, Scottsdale, Arizona. “MeTAMorphosis of Protein S – insights into the pathogenesis of Inflammatory bowel disease”.
2013 Immunobiology Seminar Series, Division of Biological Sciences, UCSD, San Diego,CA. “MeTAMorphosis of Protein S”.
2013 LXI Annual Meeting, Argentinean Society of Immunology. Los Cocos, Cordoba, Argentina. “TAMing Inflammation”.
2013 First Argentinean Spring Course on Advanced Immunology. Los Cocos, Cordoba, Argentina. “Resolution of Inflammation”.
2013 F.M. Kirby Foundation Inflammation & Signaling Symposium, Fox Chase Cancer Center, Philadelphia. “MeTAMorphosis of Protein S in Immunity”.
2013 Nijmegen Centre for Molecular Life Sciences, Radboud University of Nijmegen, Netherlands. “MeTAMorphosis of Protein S”.
2013 New Perspectives in Basic and Applied Immunology Symposium, DKFZ German Cancer Research Center, Heidelberg, Germany. “MeTAMorphosis of Protein S”.
2013 Seminar Series, Genentech, South San Francisco, CA. “MeTAMorphosis of Protein S”
2013 Immunology Seminar Series, Massachusetts General Hospital Center For Immunology & Inflammatory Diseases (CIID), Boston, MA. “MeTAMorphosis of Protein S”
2012 Microbiology, Immunology and Cancer Biology seminar series, University of Virginia, Charlottesville, VA. “TAMing Inflammation”
2012 Immunology and Virology Program Spring Seminar Series, University of Massachusetts Worcester, MA. “TAMing Inflammation”.
2011 FASEB Autoimmunity Conference, VT. “ Tyro3, Axl and Mer reprogram Type I IFN receptor signaling and control autoimmunity”
2011 Seminar Series on Immunity & Inflammation, NCI-NIH, Frederick, MD. “TAMing inflammation”.
2011 Laboratory of Parasitic Diseases, NIAID-NIH, Bethesda, MD. “TAMing inflammation”.
2011 Abbott Immunology. Worcester, MA. “TAM Receptor Tyrosine Kinases reprogram Type I IFN signaling to control autoimmunity”.
2011 Centers for Therapeutic Innovation Pfizer. Cambridge, MA. “TAMing inflammation”.
2010 Autoimmunity Center Seminar, Temple University, Philadelphia, PA. “TAM receptors are pleiotropic inhibitors of the innate immune response”.
2010 16th Inflammation Research Association International Conference, Chantilly, VA. “TAMing inflammation in vivo”.
2010 Innate Immunity: Mechanisms Linking with Adaptive Immunity, Keystone Symposia. Dublin, Ireland. “TAMing inflammation in vivo”.
2010 Department of Pathology, Albert Einstein College of Medicine, Bronx, NY. “TAMing inflammation”.
2010 Department of Biochemistry/Molecular Biology, UMDNJ-New Jersey Medical School, Newark, NJ. “TAMing inflammation”.
2010 Committee on Immunology Seminar Series, University of Chicago, Chicago, IL.“TAMing inflammation”.
2009 AAI 96th Annual Meeting, Major Symposia, Seattle, WA. “TAMing inflammation”.
2009 Midwinter Conference of Immunologists, Asilomar, CA. “TAMing inflammation”.
2008 Department of Microbiology, Tumor & Cell Biology, Karolinska Institute, Stockholm, Sweden. “TAM receptors are pleiotropic inhibitors of the innate immune response”
2008 Rheumatology, Allergy & Immunology Seminar Series, UCSD, San Diego, CA. “TAM receptors are pleiotropic inhibitors of the innate immune response”
2007 The 39th Annual meeting of the Argentinean Society of Pharmacology, Buenos Aires, Argentina. “TAM receptors are pleiotropic inhibitors of the innate immune response”
2007 Genomics Institute of the Novartis Foundation (GNF), San Diego, CA. “TAM receptors are pleiotropic inhibitors of the innate immune response”

Peer-reviewed Presentations:

2013 Keystone symposium, Type 2 Immunity: Initiation, Maintenance, Homeostasis and Pathology, Santa Fe, New Mexico. "TAMing type II immunity"
2012 Lupus Research Institute 12th Annual Scientific Conference, New York, NY. "TAMing the pathogenic Type I Interferon response in SLE".
2012 Post-Translational Regulation of Cell Signaling, Salk Institute for Biological Studies, San Diego, CA. "T cell-derived Protein S negatively feedbacks on dendritic cells to maintain immune homeostasis".
2012 Cold Spring Harbor Laboratory, Gene Expression & Signaling in the Immune System, Cold Spring Harbor, NY. "T cell-derived Protein S negatively feedbacks on dendritic cells to maintain immune homeostasis"
2012 Keystone Symposium, Innate Immunity, Sensing the Microbes and Damage Signals, Keystone, CO. "T Cell-Derived Protein S Negatively Regulates the Innate Immune Response".
2012 6th Salk Institute Symposium on Biological Complexity, Immunity & Inflammation, La Jolla, CA. "T Cell-Derived Protein S Negatively Regulates the Innate Immune Response".
2011 Advance in Inflammatory Bowel Diseases, CCFA Clinical & Research Conference, Hollywood, FL. "TAMing colitis and colitis-associated colon cancer".
2008 Innate Immunity: Signaling Mechanisms, Keystone Symposia, Keystone, CO. "TAM receptors are pleiotropic inhibitors of the innate immune response".
2007 Infectious Diseases Research Conference, UCSD, San Diego, CA. "TAM receptors are pleiotropic inhibitors of the innate immune response".
2007 Gordon Research Conference on Immunochemistry & Immunobiology, Ventura, CA. "TAM Receptor Signaling in Dendritic Cells Negatively Regulates the Innate Immune Response".
2006 The 32nd Annual La Jolla Immunology Conference, La Jolla, CA. "TAM Receptor Signaling in Dendritic Cells Negatively Regulates the Innate Immune Response".
2006 The 12th meeting on Protein Phosphorylation & Cell Signaling, The Salk Institute, San Diego, CA. "TAM receptors are pleiotropic inhibitors of the innate immune response".
2005 The 31st Annual La Jolla Immunology Conference, La Jolla, CA. "TAM receptor tyrosine kinases are pleiotropic negative regulators of the immune response"

PROFESSIONAL SERVICE

Peer Review Groups/Grant Study Sections

2022-present Member, Keystone Symposia Scientific Advisory Board
2021-present Member, National Advisory Committee Pew Latin American Fellowship Program
2021-present Member, Damon Runyon Fellowship award committee, USA
2016-2022 Permanent member**,** GMPB study section, CSR, NIH, USA
2016 Ad Hoc Referee, MIST Special Emphasis Panel, CSR, NIH, USA
2015 Ad Hoc Referee**,** GMPB study section, CSR, NIH, USA
2013-2019 Ad Hoc Referee**,** The Lupus Research Institute, USA
2013 Ad Hoc Referee, Austrian Science Fund, Austria
2012 Ad Hoc Referee, Portuguese Foundation for Science and Technology, Portugal
2011-present Ad Hoc Referee, MS Research, Australia; Veni Program
2011 Ad Hoc Referee, The Netherlands Organization for Health Research and Development
2010-present Ad Hoc Referee, FonCyT, Argentina

Journal Service

Ad Hoc Reviewer**:** *Cell, Cell Systems, eLife, EMBO Journal, Immunity, Journal of Autoimmunity, Journal of Leukocyte Biology, Mucosal Immunology, Nature, Nature Immunology, PLoS Neglected Tropical Diseases, PLoS One, PLoS Pathogens, PNAS, Science*, *Science Signaling*, *Science Advances*, *The*

FASEB Journal, The Journal of Experimental Medicine, The Journal of Leukocyte Biology, The Journal of Neuroscience, The Journal of Immunology.

Professional Service for Professional Organizations

Committees:

2018- present	Minority Affairs Committee	Member
	The American Association of Immunologists	
2023- present	Council Member, International Cytokine and Interferon Society	

Editorial, Advisory Boards and Consulting:

2022-present	Trends in Immunology	Advisory Board
2023-present	Journal of Experimental Medicine	Advisory Editor Board
2022-present	Janssen Immunology	Council Member
April 2020- 2024	eLife	Senior Editor
2019- March 2020	eLife	Reviewing Editor
2024- present	BioMed X Institute	Consultant and Academic Mentor
2024- present	Illimis Therapeutics	Consultant
2024- present	ZOLL Medical, TherOx	Member SAB
2019- present	Janssen Immunology	Member SAB
2019- present	Roche	Immunology Incubator Board
2019- present	Immunology & Cell Biology	Editorial Board Member
2019- present	Decode Consortium	External Advisory Board Member
2018- present	Life Science Alliance	Member Advisor Editorial Board
2018- present	ImCORE	Member Oversight Committee
2014-2023	Surface Oncology	Scientific Founder and SAB member

Meeting Planning:

2026 Gordon Conference, Immunohistochemistry and Immunobiology
Co-chair with Dr. Matteo Ianaconne.

2024 Gordon Conference, Immunohistochemistry and Immunobiology
Co-chair elect with Dr. Matteo Ianaconne.

2024 Keystone Symposia. “Inhibitory receptors in immune homeostasis, disease and therapy”
June 12-17, 2024 | Beaver Run Resort, Colorado, USA.
Scientific Organizers: Linde Meyaard, Jonathon Sedgwick, Carla V. Rothlin and Alex McCarthy

2022 Keystone Symposia. “Resolution of Inflammation”
June 12-17, 2022 | Keystone, Colorado, USA.
Scientific Organizers: Carla V. Rothlin, Kodi S. Ravichandran, Ashley W. Seifert and Gabrielle Fredman

2022 EMBO Conference. “Phagocytosis of dying cells: Molecules, mechanisms, and therapeutic implications”
September 12-15, 2022 | Ghent, Belgium
Scientific Organizers: Kodi S. Ravichandran, Brigitte Galliot, Francesca Peri, Peter Vandenabeele and Carla V. Rothlin.

2019 Keystone Symposia. “Uncovering Mechanisms from Immune-Based Therapy in Cancer and Autoimmunity”
February 18 - 22, 2019 | Breckenridge, Colorado, USA
Scientific Organizers: Daniel J. Cua, E. John Wherry and Carla V. Rothlin

2018 Chair, Major Symposium: "Gone but not Forgotten: The Impact of Cell Death on the Immune Response". American Association of Immunologists Annual Meeting. May 4-8, Austin, Texas, USA.

2011-2015 Organizer, Yale Immunobiology Retreat, Jiminy Peak, Hancock, MA.

2004 Co-organizer, "Partners in the Mercosur, Partners in Neuroscience: Brazil and Argentina Get Together in San Diego" Society for Neuroscience 34th annual meeting, San Diego, CA. with Dr. Stevens Rehen, Research Associate, The Scripps Research Institute

Yale University Service: Medical School

2021 - present	Member, Executive Committee, Status of Women in Medicine (SWIM).
2019 - present	Co-Leader, Cancer Immunology Program, Yale Cancer Center
2018 - present	Director of Graduate Studies, Department of Immunobiology.
2021 - 2023	Member, Search Committee for Faculty positions, Center of Molecular and Cellular Oncology.
2021 - 2022	Member, Search Committee for Joseph and Lucille Madri Professorship in Pathology.
2021 - 2022	Member, Search Committee for Faculty positions, Chemical Biology Institute and Immunobiology.
2018 – 2019	Co-Chair, Faculty Engagement Committee.
2018 - 2019	Member, Search Committee for Director of Immuno-Oncology Center.
2018	Member, Search Committee for Director of Neuro-oncology.
2018 - 2019	Member, Search Committee for Faculty positions in Immunobiology.
2017- present	Faculty Member, Diversity and Climate Committee, Department of Immunobiology. This committee is formed by students, Post-Docs and Faculty and aims to identify mechanisms that promote diversity and inclusion towards an improved climate in the Department.
2012-2018	Member, MD PhD Faculty Committee, Yale University.
2015-2017	Member, Faculty Search Committee for Computational Immunobiology.
2015-2017	Departmental Liason, Status of Women in Medicine (SWIM).
2016	Member, Faculty Search Committee for Human Translational Immunology.
2015	Member, YCC Strategic Planning Committee on Translational Immuno-oncology.
2011-2015	Chair, Yale Immunobiology Annual Retreat.

Public Service

I am the co-founder of "Globlal Immunotalks" together with Dr. Elina I. Zuniga, Professor, UCSD. These are a series of weekly talks presented by thought leaders in immunology. A goal of the series is to help close the divide between those in the scientific community who have regular access to these kinds of talks and those who do not. The talks cover the latest in science, delivered by the discoverers themselves. The talks are delivered via Zoom at noon Eastern Time, and then uploaded in YouTube and Bibibili channels.

I am the inaugural course director of Global Immunocourse. The first course was held in December 2023 at the Indian Institute of Science, Bangalore, India. The second course was held in December 2024 at Ashoka University, Haryana, India. Global Immunocourses are designed to introduce the fundamentals of immunology in an engaging manner while fostering a global community of passionate immunologists.

I was the keynote speaker at the 2022 Yale Day of Immunology and the keynote speaker Dr. Anton Bennet and Dr. Titilayo Omotade Distinguished Lecture at the 2022 Yale Biological and Biomedical Sciences Diversity and Inclusion Collective Research Symposium.

I was an advocate for the Lupus community and the work of the Lupus Research Institute. I have presented our research efforts in fundraisers as well as conferences aimed at sharing our discoveries with Lupus patients.

I was the co-organizer, "Partners in the Mercosur, Partners in Neuroscience: Brazil and Argentina Get Together in San Diego" Society for Neuroscience 34th annual meeting, San Diego, CA. with Dr. Stevens Rehen, Research Associate, The Scripps Research Institute.

I have volunteered to teach at:
-First Argentinean Spring Course on Advanced Immunology, Cordoba, Argentina (November 2013)
-Immunology Schools organized by the International Union of Immunology Societies (IUIS) in Fez, Morocco (March 2018) and Marrakesh, Morocco (December 2018)
-Yale-CAPES Seminar of in Biological Science at Porto Alegre, Brazil (December 2019).
- IUIS Course on "Mechanisms and approaches to immunotherapy for cancer and chronic inflammatory diseases", Colombia (virtual).

Peer-Reviewed Publications:

1) **Rothlin C V**, Katz E, Verbitsky M, Elgoyhen A B. (1999) The α9 Nicotinic Acetylcholine Receptor Shares Pharmacological Properties with Type A Gamma-Aminobutyric Acid, Glicine, and Type 3 Serotonin Receptors. ***Mol Pharmacol*.** 1999 Feb;55(2):248-54. PMID: 9927615.
2) Katz E, Verbitsky M, **Rothlin C V**, Vetter D E, Heinemann S F and Elgoyhen A B. (2000) High Calcium Permeability and Calcium Block of the α9 Nicotinic Acetylcholine Receptor. ***Hear Res*.** 2000 Mar;141(1-2):117-28. PMID: 10713500.
3) **Rothlin C V**, Katz E, Verbitsky M, Vetter D E, Heinemann S F and Elgoyhen A B. (2000) Block of the α9 nAChr by Ototoxic Aminoglycosides. ***Neuropharmacology***. 2000 Oct;39(13):2525-32. PMID: 11044724
4) Verbitsky M, **Rothlin C V**, Katz E and Elgoyhen A B. (2000) Mixed Muscarinic-Nicotinic Properties of the α9 nAChR. ***Neuropharmacology***. 2000 Oct;39(13):2515-24. PMID: 11044723
5) Elgoyhen B, Vetter D E, Katz E, **Rothlin Carla V**, Heinemann S and Boulter J. (2001) Alpha 10: A Determinant Of Nicotinic Cholinergic Receptor Function In Mammalian Vestibular and Cochlear Mechanosensory Hair Cells. ***Proc Natl Acad Sci U S A***. 2001 Mar 13;98(6):3501-6. PMID: 11248107.
6) **Rothlin C V**, Lioudyno M I, Silbering A F, Plazas P V, Casati M E, Katz E, Guth P S, Elgoyhen A B. (2003) Direct Interaction of Serotonin Type 3 Receptor Ligands With Recombinant and Native Alpha 9 Alpha 10-Containing Nicotinic Cholinergic Receptors. ***Mol Pharmacol*.** 2003 May;63(5):1067-74. PMID: 12695535.
7) Ballestero J A, Plazas P V, Kracun S, Gomez-Casati M E, Taranda J, **Rothlin C V**, Katz E, Millar N S, Elgoyhen A B. (2005) Effects of Quinine, Quinidine and Chloroquine on α9 α10 Nicotinic Cholinergic Receptors. ***Mol Pharmacol*.** 2005 Sep;68(3):822-9. Epub 2005 Jun 13. PMID: 15955868.
8) Sharif M N, Sosic D, **Rothlin C V**, Kelly E, Lemke G, Olson E N, Ivashkiv L B. (2006) Twist Mediates Suppression Of Inflammation By Type I IFNs and Axl. ***J Exp Med.*** 2006 Aug 7;203(8):1891-901. Epub 2006 Jul 10. PMID: 16831897.
9) Prasad D, **Rothlin C V**, Burrola P, Burstyn-Cohen T, Lu Q, Garcia de Frutis P, Lemke G. (2006) TAM Receptor Function in the Retinal Pigment Epithelium. ***Mol Cell Neurosci*.** 2006 Sep;33(1):96-108. Epub 2006 Aug 9. PMID: 16901715.
10) *Ghosh S, *Tergaonkar V, **Rothlin C V**, Correa R G, Bottero V, Bist P, Verma I M, Hunter T. (2006) Essential Role of Tuberous Sclerosis Genes *TSC1* and *TSC2* in NF-kappaB Activation and Cell Survival. *Both authors contributed equally to this work. ***Cancer Cell*.** 2006 Sep;10(3):215-26. PMID: 16959613.
11) **Rothlin C V,** Ghosh S, Zuniga EI, Oldstone MB, Lemke G. (2007) TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response. ***Cell*.** Dec 14;131(6):1124-36. PMID: 18083102.
12) van den Brand BT, Abdollahi-Roodsaz S, Vermeij EA, Bennink MB, Arntz OJ, **Rothlin CV**, van den Berg WB, van de Loo FA. (2013) Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase agonists

in collagen-induced arthritis. ***Arthritis Rheum.*** Mar;65(3):671-80. doi: 10.1002/art.37786. PMID: 23203851.

13) Carrera Silva E, Chan P, Joannas L, Errasti E, Gagliani N, Bosurgi L, Jabbour M, Perry A, Smith-Chakmakova F, Mucida D, Cheroutre H, Burstyn-Cohen T, Leighton J, Lemke G, Ghosh S, **Rothlin C V.** T cell-derived Protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response (2013). ***Immunity,*** Jul; 39(1): 160-170, PMID: 23850380
14) Bosurgi L, Bernink J, Delgado Cuevas V, Gagliani N, Joannas L, Schmid ET, Booth CJ, Ghosh S, **Rothlin C V**. (2013) Paradoxical role of the proto-oncogenes Axl and Mer receptor tyrosine kinases in colon cancer. ***Proc Natl Acad Sci U S A***, Aug 6; 110(32): 13091-6. PMID: 23878224.
15) Bhattacharyya S, Zagórska A, Lew ED, Shrestha B, **Rothlin C V**, Naughton J, Diamond MS, Lemke G and Young JAT. (2013) Enveloped viruses disable innate immune responses in dendritic cells via direct activation of TAM Receptors. ***Cell Host Microbe***, Aug 14; 14(2): 136-47. PMID: 23954153.
16) Kusne Y, Carrera Silva E, Perry AS, Rushing EJ, Mandell EK, Dietrich J, Errasti A, Gibbs D, Berens ME, Loftus JC, Hulme C, Aldape K, Sanai N, **Rothlin CV*** and Ghosh S*. (2014) Tumor intrinsic EGFR and macrophage induced TNF-α signaling cooperate to promote GBM progression through aPKC. * co-corresponding authors. ***Science Signaling***, 7(338), ra75. PMID: 25118327.
17) Cabezón R, Carrera-Silva EA, Flórez-Grau G, Errasti AE, Calderón-Gómez E, Lozano JJ, España C, Ricart E, Panés J, **Rothlin CV**, Benítez-Ribas D. (2015) MERTK as negative regulator of human T cell activation. ***J Leukoc Biol***. 2015 Apr;97(4):751-60. doi: 10.1189/jlb.3A0714-334R. Epub 2015 Jan 26.PMID: 25624460
18) Bárcena C, Stefanovic M, Tutusaus A, Joannas L, Menéndez A, García-Ruiz C, Sancho-Bru P, Marí M, Caballeria J, **Rothlin CV**, Fernández-Checa JC, García de Frutos P, Morales A. (2015) Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. ***J Hepatol****.* Apr 20. [Epub ahead of print] PMID: 25908269.
19) Chae WJ, Ehrlich AK, Chan PY, Teixeira AM, Henegariu O, Hao L, Shin JH, Park JH, Tang WH, Kim ST, Maher SE, Goldsmith-Pestana K, Shan P, Hwa J, Lee PJ, Krause DS, **Rothlin CV**, McMahon-Pratt D, Bothwell AL. (2016). The Wnt antagonist Dickkopf-1 promotes pathological type 2 cell-mediated inflammation. ***Immunity****.* Feb 16;44(2):246-58. doi: 10.1016/j.immuni.2016.01.008. PMID: 26872695.
20) Fourgeaud L, Través PG, Tufail Y, Leal-Bailey H, Lew ED, Burrola PG, Callaway P, Zagórska A, **Rothlin CV**, Nimmerjahn A, Lemke G. (2016). TAM receptors regulate multiple features of microglial physiology. ***Nature***, 532(7598):240-4. PMID: 27049947.
21) Chan PY, Carrera Silva E, De Kouchkovsky D, Joannas L, Hao L, Hu D, Huntsman S, Eng C, Licona-Limón P, Weinstein J, Herbert D, Craft JE, Flavell RA, Repetto S, Correale J, Burchard EG, Torgerson DG, Ghosh S, **Rothlin CV**. (2016). The TAM family receptor tyrosine kinase TYRO3 is a Negative Regulator of Type 2 Immunity**.** ***Science***, 352(6281): 99-103. PMID: 27034374.
22) Schmid ET, Pang IK, Carrera Silva EA, Bosurgi L, Miner JJ, Diamond MS, Iwasaki A, **Rothlin CV**. (2016). AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity. ***eLIFE***, 5:e12414. DOI: 10.7554/eLife.12414. PMID: 27350258.
23) Spadaro O, Camell CD, Bosurgi L, Nguyen KY, Youm YH, **Rothlin CV**, Dixit VD. (2017). IGF1 Shapes Macrophage Activation in Response to Immunometabolic Challenge. ***Cell Rep.*** 19(2):225-234. PMID: 28402847.
24) Hastings AK, Yockey LJ, Jagger BW, Hwang J, Uraki R, Gaitsch HF, Parnell LA, Cao B, Mysorekar IU, **Rothlin CV**, Fikrig E, Diamond MS, Iwasaki A. (2017). TAM Receptors Are Not Required for Zika Virus Infection in Mice. ***Cell Rep***. 19(3):558-568. PMID: 28423319.
25) A-Gonzalez N, Quintana JA, García-Silva S, Mazariegos M, González de la Aleja A, Nicolás-Ávila JA, Walter W, Adrover JM, Crainiciuc G, Kuchroo VK, **Rothlin CV**, Peinado H, Castrillo A, Ricote M, Hidalgo A. Phagocytosis imprints heterogeneity in tissue-resident macrophages. (2017). ***J Exp Med.*** 214(5):1281-1296. PMID: 28432199.
26) Bosurgi L, Cao YG, Cabeza-Cabrerizo M, Tucci A, Hughes LD, Kong Y, Weinstein JS, Licona-Limon P, Schmid ET, Pelorosso F, Gagliani N, Craft JE, Flavell RA, Ghosh S, **Rothlin CV**. (2017). Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. ***Science***. 356 (6342):1072-1076. PMID: 28495875.

27) Uribe DJ, Mandell EK, Watson A, Martinez JD, Leighton JA, Ghosh S, **Rothlin CV**. (2017). The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer. ***PLoS One***. Jul 20;12(7):e0179979. PMID: 28727830.
28) DeBerge M, Yeap XY, Dehn S, Zhang S, Grigoryeva L, Misener S, Procissi D, Zhou X, Lee DC, Muller WA, Luo X, **Rothlin CV**, Tabas I, Thorp EB. MerTK Cleavage on Resident Cardiac Macrophages Compromises Repair After Myocardial Ischemia Reperfusion Injury. (2017). ***Circ Res***. Sep 29;121(8):930-940. PMID: 28851810.
29) Cross SN, Potter JA, Aldo P, Kwon JY, Pitruzzello M, Tong M, Guller S, **Rothlin CV**, Mor G, Abrahams VM. (2017). Viral Infection Sensitizes Human Fetal Membranes to Bacterial Lipopolysaccharide by MERTK Inhibition and Inflammasome Activation. ***J Immunol.*** Oct 15;199(8):2885-2895. PMID:28916522.
30) Chang CF, Goods BA, Askenase MH, Hammond MD, Renfroe SC, Steinschneider AF, Landreneau MJ, Ai Y, Beatty HE, da Costa LHA, Mack M, Sheth KN, Greer DM, Huttner A, Coman D, Hyder F, Ghosh S, **Rothlin CV**, Love JC, Sansing LH. (2018). Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage. ***J Clin Invest.*** Feb 1;128(2):607-624. PMID: 29251628.
31) Mulla MJ, Weel IC, Potter JA, Gysler SM, Salmon JE, Peraçoli MTS, **Rothlin CV**, Chamley LW, Abrahams VM. (2018). Antiphospholipid Antibodies Inhibit Trophoblast Toll-Like Receptor and Inflammasome Negative Regulators. ***Arthritis Rheumatol.*** 70 (6), 891-902. 2018. doi: 10.1002/art.40416. PMID: 29342502.
32) Cai B, Dongiovanni P, Corey KE, Wang X, Shmarakov IO, Zheng Z, Kasikara C, Davra V, Meroni M, Chung RT , **Rothlin CV**, Schwabe RF, Blaner WS, Birge RB, Valenti L, Tabas I. (2020) Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. ***Cell Metabolism***. Feb 4;31(2):406-421.e7. PMID 31839486.
33) Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, Chudnovskiy A, Maskey S, Walker L, Finnigan JP, Kirkling ME, Reizis B, Ghosh S, D'Amore NR, Bhardwaj N, **Rothlin CV**, Wolf A, Flores R,Marron T, Rahman AH, Kenigsberg E, Brown BD and Merad M. (2020). A conserved dendritic-cell regulatory program limits antitumour immunity. ***Nature***. 580, 257–262. PMID: 32269339
34) Damisah EC, Hill RA, Rai A, Chen F, **Rothlin CV**, Ghosh S, Grutzendler J. (2020) Astrocytes and microglia play orchestrated roles and respect phagocytic territories during neuronal corpse removal in vivo. ***Science Advances***. Vol. 6, no. 26, eaba3239. PMID: 32637606.
35) Nicolás-Ávila JA, Lechuga-Vieco AV, Esteban-Martínez L, Sánchez-Díaz M, Díaz-García E, Santiago DJ, Rubio-Ponce A, Li JL, Balachander A, Quintana JA, Martínez-de-Mena R, Castejón-Vega B, Pun-García A, Través PG, Bonzón-Kulichenko E, García-Marqués F, Cussó L, A-González N, González-Guerra A, Roche-Molina M, Martin-Salamanca S, Crainiciuc G, Guzmán G, Larrazabal J, Herrero-Galán E, Alegre-Cebollada J, Lemke G, **Rothlin CV**, Jimenez-Borreguero LJ, Reyes G, Castrillo A, Desco M, Muñoz-Cánoves P, Ibáñez B, Torres M, Ng LG, Priori SG, Bueno H, Vázquez J, Cordero MD, Bernal JA, Enríquez JA, Hidalgo A. (2020). A network of Macrophages supports mitochondrial homeostasis in the heart. ***Cell***. Oct 1;183(1):94-109.
36) Ortiz Wilczyñski JM, Olexen CM, Errasti AE, Schattner M, **Rothlin CV**, Correale J, Carrera Silva EA. (2020) GAS6 signaling tempers Th17 development in patients with multiple sclerosis and helminth infection. ***PLoS Pathog***. Dec 21;16(12):e1009176. doi: 10.1371/journal.ppat.1009176. PMID: 33347509.
37) DeBerge M, Glinton K, Subramanian M, Wilsbacher LD, **Rothlin CV,** Tabas T, Thorp EB. (2021). Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction. ***J Clin Invest.*** Mar 15;131(6):e139576. PMID: 33529176.
38) Wanke F, Gutbier S, Rümmelin A, Steinberg M, Hughes LD, Koenen M, Komuczki J, Regan-Komito D, Wagage S, Hesselmann J, Thoma R, Brugger D, Christopeit T, Wang H, Point F, Hallet R, Ghosh S, **Rothlin CV**, Patsch C, Geering B. (2021) Ligand-dependent kinase activity of MERTK drives efferocytosis in human iPSC-derived macrophages. ***Cell Death Dis.*** May 25;12(6):538. doi: 10.1038/s41419-021-03770-0. PMID: 34035216.
39) Tirado-Gonzalez I, Descot A, Soetopo D, Nevmerzhitskaya A, Schaffer A, Kur IM, Czlonka E, Wachtel C, Tsoukala I, Muller L, Schafer AL, Weitmann M, Dinse P, Alberto E, Buck MC, Landry JJM, Baying B, Slotta-Huspenina J, Roesler J, Harter PN, Kubasch AS, Meinel J, Elwakeel E, Strack

E, Tran Quang C, Abdel-Wahab O, Schmitz M, Weigert A, Schmid T, Platzbecker U, Benes V, Ghysdael J, Bonig H, Gotze KS, **Rothlin CV**, Ghosh S, Medyouf H. (2021) AXL inhibition in macrophages stimulates host-versus-leukemia immunity and eradicates naive and treatment resistant leukemia. ***Cancer Discov***. Jun 8: candisc.1378. 2020. doi: 10.1158/2159-8290.CD-20-1378. Online ahead of print. PMID: 34103328

40) Goyette MA, Elkholi IE, Apcher C, Kuasne H, **Rothlin CV**, Muller WJ, Richard DE, Park M, Gratton JP, Côté JF. (2021). Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels. ***Proc Natl Acad Sci U S A***. Jul 20;118(29):e2023868118. doi: 10.1073/pnas.2023868118. PMID: 34266948.
41) Zhao L, Giannou AD, Xu Y, Shiri AM, Liebold I, Steglich B, Bedke T, Zhang T, Lücke J, Scognamiglio P, Kempski J, Woestemeier A, Chen J, Agalioti T, Zazara DE, Lindner D, Janning M, Hennigs JK, Jagirdar RM, Kotsiou OS, Zarogiannis SG, Kobayashi Y, Izbicki JR, Ghosh S, **Rothlin CV**, Bosurgi L, Huber S, Gagliani N. (2021). Efferocytosis fuels malignant pleural effusion through TIMP1. ***Science Advances***. Aug 13;7(33):eabd6734. doi: 10.1126/sciadv.abd6734. PMID: 34389533
42) Silva-Filho JL, de Oliveira LG, Monteiro L, Parise PL, Zanluqui NG, Polonio CM, de Freitas CL, Toledo-Teixeira DA, de Souza WM, Bittencourt N, Amorim MR, Forato J, Muraro SP, de Souza GF, Martini MC, Bispo-Dos-Santos K, Vieira A, Judice CC, Pastore GM, Amaral E, Passini Junior R, Mayer-Milanez HMBP, Ribeiro-do-Valle CC, Calil R, Renato Bennini Junior J, Lajos GJ, Altemani A, Nolasco da Silva MT, Carolina Coan A, Francisca Colella-Santos M, von Zuben APB, Vinolo MAR, Arns CW, Catharino RR, Costa ML, Angerami RN, Freitas ARR, Resende MR, Garcia MT, Luiza Moretti M, Renia L, Ng LFP, **Rothlin CV**, Costa FTM, Peron JPS, Proença-Modena JL. (2021). Gas6 drives Zika virus-induced neurological complications in humans and congenital syndrome in immunocompetent mice. ***Brain Behav Immun.*** 2021 Oct;97:260-274. doi: 10.1016/j.bbi.2021.08.008. Epub 2021 Aug 11. PMID: 34390806
43) Guo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, **Rothlin CV**, Kluger HM, Desir GV (2022). Inhibition of renalase drives tumour rejection by promoting T cell activation. ***Eur J Cancer.*** Apr;165:81-96. doi: 10.1016/j.ejca.2022.01.002. Epub 2022 Feb 24. PMID: 35219026
44) Mederacke I, Filliol A, Affo S, Nair A, Hernandez C, Sun Q, Hamberger F, Brundu F, Chen Y, Ravichandra A, Huebener P, Anke H, Shi H, Martínez García de la Torre RA, Smith JR, Henderson NC, Vondran FWR, **Rothlin CV**, Baehre H, Tabas I, Sancho-Bru P, Schwabe RF. (2022). The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver. ***Sci Transl Med***. Apr 6;14(639):eabe5795. doi: 10.1126/scitranslmed.abe5795. Epub 2022 Apr 6.
45) Sekar D, Christina Dillmann, Evelyn Sirait-Fischer, Annika Fink, Aleksandra Zivkovic, Natalie Baum, Elisabeth Strack, Stephan Klatt, Sven Zukunft, Stefan Wallner, Arnaud Descot, Catherine Olesch, Priscila da Silva, Andreas von Knethen, Tobias Schmid, Sabine Groesch, Rajkumar Savai, Nerea Ferreiròs, Ingrid Fleming, Sourav Ghosh, **Rothlin CV**, Holger Stark, Hind Medyouf, Bernhard Brüne, and Andreas Weigert (2022). Phosphatidylserine synthase PTDSS1 shapes the tumor lipidome to maintain tumor-promoting inflammation. ***Cancer Research.*** Apr 15;82(8):1617-1632.
46) Akalu YT, Mercau ME, Ansems M, Hughes LD, Nevin J, Alberto EJ, Liu XN, He LZ, Alvarado D, Keler T, Kong Y, Philbrick WM, Bosenberg M, Finnemann SC, Iavarone A, Lasorella A, **Rothlin CV***, Ghosh S*. * co-corresponding authors. (2022). Tissue-specific modifier alleles determine *Mertk* loss-of-function traits. ***Elife***. Aug 15;11:e80530. doi: 10.7554/eLife.80530. PMID: 35969037
47) Engelmann J, Zarrer J, Gensch V, Riecken K, Berenbrok N, Luu TV, Beitzen-Heineke A, Vargas-Delgado ME, Pantel K, Bokemeyer C, Bhamidipati S, Darwish IS, Masuda E, Burstyn-Cohen T, Alberto EJ, Ghosh S, **Rothlin C**, Hesse E, Taipaleenmäki H, Ben-Batalla I, Loges S (2022). Regulation of bone homeostasis by MERTK and TYRO3. ***Nat Commun.*** Dec 12;13(1):7689. doi: 10.1038/s41467-022-33938-x. PMID: 36509738
48) Mercau ME, Akalu YT, Mazzoni F, Gyimesi G, Alberto EJ, Kong Y, Hafler B, Finnemann SC*, **Rothlin CV***, Ghosh S*. * co-corresponding authors. (2023) Inflammation of the Retinal Pigment Epithelium drives early-onset photoreceptor degeneration in Mertk-associated retinitis pigmentosa. ***Science Advances***. Jan 20;9(3):eade9459. doi: 10.1126/sciadv.ade9459. PMID: 36662852.

49) Pramio D, Monteleone Vieceli F , Varella-Branco E, Purcell Goes C, Kobayashi GS, Vieira da Silva Pelegrina D, de Moraes BC, El Allam A, De Kumar B, Jara G, Farfel JM, Bennett DA, Kundu S, Viapiano MS, Moraes Reis E, Lopes de Oliveira PS, Dos Santos E Passos-Bueno MR , **Rothlin CV**, Ghosh S, Schechtman D. (2023) DNA methylation of the promoter region at the CREB1 binding site is a mechanism for the epigenetic regulation of brain-specific PKMζ. ***Biochim Biophys Acta Gene Regul Mech***. Mar;1866(1):194909. PMID: 36682583
50) Bee GCW, Lokken-Toyli KL, Yeung ST, Rodriguez L, Zangari T, Anderson EE, Ghosh S, **Rothlin CV**, Brodin P, Khanna KM, Weiser JN. (2023) Age-dependent differences in efferocytosis determine the outcome of opsonophagocytic protection from invasive pathogens. ***Immunity***. Apr 5:S1074-7613(23)00138-3. doi: 10.1016/j.immuni.2023.03.018.
51) Hamley M, Leyk S, Casar C, Liebold I, Jawazneh AA, Lanzloth C, Böttcher M, Haas H, Richardt U, **Rothlin CV**, Jacobs T, Huber S, Adlung L, Pelczar P, Henao-Mejia J, Bosurgi L. (2023) Nmes1 is a novel regulator of mucosal response influencing intestinal healing potential. ***Eur J Immunol.*** Nov 16:e2350434. doi: 10.1002/eji.202350434.
52) Liebold I, Jawazneh AA, Casar C, Lanzloth C, Leyk S, Hamley M, Wong MN, Kylies D, Gräfe SK, Edenhofer I, Pardos IA, Kriwet M, Haas H, Krause J, Hadjilaou A, Schromm AB, Richardt U, Eggert P, Tappe D, Weidemann SA, Ghosh S, Krebs CF, Gonzalez NA, Worthmann A, Lohse AW, Huber S, **Rothlin CV**, Puelles VG, Jacobs T, Gagliani N, Bosurgi L. (2024) Apoptotic cell identity induces distinct functional responses to IL-4 in efferocytic macrophages. **Science** Apr 5;384(6691):eabo7027. doi: 10.1126/science.abo7027. PMID: 38574142
53) Zachary Even, Alexandre P. Meli, Antariksh Tyagi, Aurobind Vidyarthi, Neima Briggs, Dimitri A. de Kouchkovsky, Yong Kong, Yaqiu Wang, Daniel A. Waizman, Tyler A. Rice, Bony de Kumar, Xusheng Wang, Noah W. Palm, Joe Craft, Malay K. Basu, Sourav Ghosh* and **Rothlin CV***. * co-corresponding authors. (2024) The amalgam of naïve CD4+ T cell transcriptional states is reconfigured by helminth infection to dampen the amplitude of the immune response. **Immunity** Aug 13;57(8):1893-1907. doi: 10.1016/j.immuni.2024.07.006. PMID: 39096910
54) Katherine S. Stewart, Kevin Au Gonzales, Shaopeng Yuan, Matthew T. Tierney, Alain R. Bonny, Yihao Yang, Nicole R. Infarinato, Christopher J. Cowley, John M. Levorse, Hilda Amalia Pasolli, Sourav Ghosh, **Rothlin CV** and Elaine Fuchs. (2024) Stem cells tightly regulate dead cell clearance to maintain tissue fitness. **Nature.** Aug 21. doi: 10.1038/s41586-024-07855-6.

Preprints or submitted manuscripts

1) Meriem Belabed, Matthew D. Park, Cédric M. Blouin, Sreekumar Balan, Chang Y. Moon, Jesse Boumelha, Ante Peros, Raphaël Mattiuz, Amanda M. Reid, Camillia S. Azimi, Nelson M. LaMarche, Leanna Troncoso, Angelo Amabile, Jessica Le Berichel, Steven T. Chen, C. Matthias Wilk, Brian D. Brown, Kristen Radford, Sourav Ghosh, **Rothlin CV**, Laurent Yvan-Charvet, Thomas U. Marron, Daniel J. Puleston, Nina Bhardwaj, Christophe Lamaze, Miriam Merad. AXL limits the mobilization of cholesterol to regulate dendritic cell maturation and the immunogenic response to cancer. **bioRxiv** 2023.12.25.573303; doi: https://doi.org/10.1101/2023.12.25.573303. Accepted in **Nature Immunology**
2) Zhang L, He CH, Coffey S, Yin D, Hsu IU, Su C, Ye Y, Zhang C, Spurrier J, Nicholson L, **Rothlin CV**, Ghosh S, Gopal PP, Hafler DA, Zhao H, Strittmatter SM. Single-cell transcriptomic atlas of Alzheimer's disease middle temporal gyrus reveals region, cell type and sex specificity of gene expression with novel genetic risk for MERTK in female. ***MedRxiv***. 2023 Feb 23:2023.02.18.23286037. doi: 10.1101/2023.02.18.23286037. Preprint.
3) Janik Engelmann, Jennifer Zarrer, Max Schmerder, Christian Mess, Deniz Ragipoglu, Kristoffer Riecken, Tal Burstyn-Cohen, Emily J. Alberto, Sourav Ghosh, **Rothlin CV**, Klaus Pantel, Carsten Bokemeyer, Eric Hesse, Hanna Taipaleenmäki, Sonja Loges, Isabel Ben-Batalla. TAM receptors control actomyosin dynamics in osteoclasts via RHOA-COFILIN-MYOSIN II signaling. **bioRxiv** 2024.04.12.589232; doi: https://doi.org/10.1101/2024.04.12.589232
4) Maria E. Mercau, Rieke-Marie Hackbarth, Xinran Liu, Haowei Wang, Le Zhang, Malay K. Basu, **Rothlin CV***, Sourav Ghosh*. * co-corresponding authors. Time-resolved function of cell polarity kinases PRKCZ and PRKCI in CNS myelination. **bioRxiv** 2024.04.22.589759; doi: https://doi.org/10.1101/2024.04.22.589759

5) Aicha El Ellam, Emily J. Alberto, Maria E. Mercau, Dimitrius T. Pramio, Krishna M. Bhat, William M Philbrick, Deborah Schechtman, **Rothlin CV***, Sourav Ghosh*. * co-corresponding authors. Functional roles of neural aPKCs in mouse brain development and survival. **bioRxiv** 2024.05.22.595312; doi: https://doi.org/10.1101/2024.05.22.595312
6) Maria E. Mercau, Aleksandra Deczkowska, Shir Shlomi-Loubaton, Eyal David, Assaf Weiner, Zhong-wu Liu, Yuki Yasumoto, Haowei Wang, Stephen M. Strittmatter, Edward B. Thorp, Xiao-Bing Gao, Tamas Horvath, Le Zhang, Ido Amit[#], **Rothlin CV*** and Sourav Ghosh*. * co-corresponding authors. AXL improves the effector function of disease-associated microglia and protects against Alzheimer's disease pathology (***submitted***).

Chapters, Books, and Reviews

1) "Medicamentos Rothlin" (Physician Desk Reference containing all commercial drug products from Argentina and clinically relevant drug-drug interactions). Director: Rodolfo Pedro Rothlin. Coordinator: Mariano Nuñez. Rothlin C.V. (collaborator). 2005 (first), 2006 and 2007 editions.
2) "Textbook of Tinnitus" Edited by Moller A.R., Langguth B., De Ridder D., Kleinjung T. CHAPTER 30, The Pharmacologist by Ana Belén Elgoyhen and Carla V. Rothlin. 2010. Springer.
3) Roth C, **Rothlin C V**, Riou S, Raulet D H, Lemke G. (2007) Stromal-Cell Regulation Of Natural Killer Cell Differentiation. ***J Mol Med (Berl)*.** 2007 Oct;85(10):1047-56. Epub 2007 Apr 11. PMID: 17426948.
4) Lemke G, **Rothlin C V**. (2008) Immunobiology of the TAM Receptors. ***Nat Rev Immunol*.** May;8(5):327-36. doi: 10.1038/nri2303. PMCID: PMC2856445.
5) **Rothlin C V,** Lemke G. (2010) TAM Receptor Signaling and Autoimmune Disease. ***Curr Opin Immunol*.** 2010 Dec;22(6):740-6 doi: 10.1016/j.coi.2010.10.001. Epub 2010 Oct 26. Review. PMID: 21030229; PMCID: PMC2997887.
6) **Rothlin CV**, Leighton j, Ghosh S. (2014). Tyro3, Axl and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. ***Inflamm Bowel Dis.*** 20(8): 1472-80. PMID: 24846720
7) **Rothlin CV**, Bosurgi L, Carrera Silva E, Ghosh S. (2015) TAM receptor signaling in immune homeostasis. ***Annual Review of Immunology***, Mar 21;33:355-91. PMID: 25594431.
8) Akalu YT, **Rothlin CV***, Ghosh S*. (2017). TAM Receptor Tyrosine Kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. * co-corresponding authors. ***Immunological Reviews*** Mar;276(1):165-17. PMID: 28258690.
9) De Kouchkovsky D, Ghosh S, **Rothlin CV**. (2017). Negative regulation of Type 2 immunity. ***Trends in Immunology*** Mar;38(3):154-167. PMID: 28082101.
10) Bosurgi L, Hughes LD, **Rothlin CV***, Ghosh S*. * co-corresponding authors. (2017). Death begets a new beginning. ***Immunol Rev.*** Nov;280(1):8-25. PMID:29027219.
11) Hughes LD, Bosurgi L, Ghosh S, **Rothlin CV**. (2017). Chronicles of Cell Death Foretold: Specificities in the Mechanism of Disposal. ***Front Immunol.*** 8:1743. doi: 10.3389/fimmu.2017.01743. PMID: 29312294.
12) Hapak SM, **Rothlin CV***, Ghosh S*. * co-corresponding authors. (2018). PAR3-PAR6-atypical PKC polarity complex proteins in neuronal polarization. **Cell Mol Life Sci**. Apr 25. doi: 10.1007/s00018-018-2828-6. PMID: 29696344.
13) Hapak SM, Ghosh S, **Rothlin CV**. (2018). Axon Regeneration: Antagonistic Signaling Pairs in Neuronal Polarization. **Trends Mol Med**. Jul;24(7):615-629. PMID: 29934283.
14) Silvina del Carmen, Sophie M. Hapak, Sourav Ghosh and **Carla V. Rothlin.** (2018). Coagulopathies and inflammatory diseases: '…glimpse of a snark'. ***Current Opinion in Immunology***, Sep 27;55:44-53. PMID: 30268838.
15) Galimberti VE, **Rothlin CV*** and Ghosh S*. * co-corresponding authors. (2019) Funerals and Feasts: The Immunological Rites of Cell Death. ***Yale J Biol Med***. PMID 31866781.
16) **Rothlin CV** and Ghosh S. (2020). Cracking the Cell Death Code. ***Cold Spring Harb Perspect Biol.*** May 1;12(5):a036343. PMID: 31548182. doi: 10.1101/cshperspect.a036343.
17) Hapak SM, **Rothlin CV**, Ghosh S. (2019). aPKC in neuronal differentiation, maturation and function. **Neuronal Signal.** Sep;3(3):NS20190019. PMID: 32269838.
18) **Rothlin CV**, Ghosh S. (2020). Lifting the innate immune barriers to antitumor immunity. ***J. Immunother Cancer.*** Apr; 8(1):e000695. PMID: 32273348.

19) Gause, WC, **Rothlin CV** and Loke P. (2020) Heterogeneity in the initiation, development and function of type 2 immunity. ***Nat Rev Immunol.*** May 4. doi: 10.1038/s41577-020-0301-x. PMID: 32367051
20) **Rothlin CV**, Hille T and Ghosh S. (2021) Determining the effector response to cell death. ***Nat Rev Immunol.*** May;21(5):292-304. doi: 10.1038/s41577-020-00456-0.
21) Hughes LD, Wang Y, Meli AP, **Rothlin CV** and Ghosh S (2021). Decoding Cell Death: From a Veritable Library of Babel to *Vade Mecum*? ***Annual Review of Immunology,*** Apr 26;39:791-817. doi: 10.1146/annurev-immunol-102819-072601. PMID: 33902311
22) **Rothlin CV** and Gutkind JS. Immunosuppressants, Immunomodulation and Tolerance, *Chapter* 35*,* ***Goodman & Gilman's: The Pharmacological Basis of Therapeutics,*** *in press.*
23) Bosurgi L, **Rothlin CV.** (2021) Management of cell death in parasitic infections. **Semin Immunopathol.** Jul 19. doi: 10.1007/s00281-021-00875-8. Online ahead of print. PMID: 34279684.
24) Mercau M, Patwa S, Bhat K, Ghosh S and **Rothlin CV**. (2022). Cell death in development, maintenance and diseases of the nervous system. **Semin Immunopathol**. May 4. doi: 10.1007/s00281-022-00938-4.
25) Vitale I, …….., **Rothlin CV**….. Galluzi L. (2023) Apoptotic cell death in disease-Current understanding of the NCCD 2023. ***Cell Death Differ.*** May;30(5):1097-1154. doi: 10.1038/s41418-023-01153-w. Epub 2023 Apr 26. PMID: 37100955
26) Ghosh S, Finnemann SC, Vollrath D, **Rothlin CV**. (2024) In the Eyes of the Beholder-New *Mertk* Knockout Mouse and Re-Evaluation of Phagocytosis versus Anti-Inflammatory Functions of MERTK. ***Int J Mol Sci.*** May 13;25(10):5299. doi: 10.3390/ijms25105299. PMID: 38791338
27) Carrera Silva, EA, Correale J, **Rothlin CV**, Ortiz Wilczyñski JM. (2024) New potential ligand-receptor axis involved in tissue repair as therapeutic targets in progressive multiple sclerosis. **J Pharmacol Exp Ther.** Oct 8:JPET-MR-2024-002254. doi: 10.1124/jpet.124.002254.

Invited Editorials and Commentaries

1) Hughes LD, Ghosh S, **Rothlin CV**. (2018). Cenabis Bene: Treg Cells Invite Macrophages to Dine. ***Immunity***. Oct 16;49(4):579-582. doi: 10.1016/j.immuni.2018.10.002. PMID: 30332622
2) de Kouchkovsky D, Ghosh S, **Rothlin CV**. (2019). Prosthetic implant debris induces sterile type 2 inflammation. ***Nature Materials***, Mar;18(3):193-194. PMID: 30783225.
3) **Rothlin CV** and Ghosh S. (2019). Serous macrophages pack Bhlhe40 for a randonnée. ***Nature Immunology***, Jun;20(6):670-671. PMID: 31061527.
4) **Rothlin CV.** (2019) Reversing Deconstruction. The Next Quarter Century. ***Immunity*****. 50 (4) 769–777.** 2019.
5) Waizman DA, Ghosh S, **Rothlin CV**. Bringing on the itch. ***eLife***. 8, Nov 29, 2019. PMID: 31782733.
6) Krummel M, Blish C, Kuhns M, Cadwell K, Oberst A, Goldrath A, Ansel KM, Chi H, O'Connell R, Wherry EJ, Pepper M; Future Immunology Consortium. (2019) Universal Principled Review: A Community-Driven Method to Improve Peer Review. ***Cell.*** 179(7):1441-1445. PMID: 31835023.
7) Crotty S, Blish C, Cadwell K, Chi H, Goldrath A, Green D, Kaech SM, Krummel M, Pepper M, **Rothlin CV**, Wherry EJ; Once-a-Year Pledge Supporters. (2020) Reinvigorating NIH Grant Peer Review ***Immunity***. 52(1):1-3. doi: 10.1016/j.immuni.2019.12.016. PMID: 31940266.
8) **Rothlin CV**, Rathinam VA, Ghosh S (2021). Editorial overview: Innate Immunity, from host defense and beyond. ***Curr Opin Immunol.*** Feb;68:iii-v. doi: 10.1016/j.coi.2021.02.005.
9) **Rothlin CV**, Ghosh S (2023) When aging gets on the way of disposal: Senescent cell suppression of efferocytosis. J Cell Biol. Feb 6;222(2):e202212023. doi: 10.1083/jcb.202212023. Epub 2023 Jan 5. PMID: 36602762
10) Ghosh S, **Rothlin CV.** (2024) TREM2 function in glioblastoma immune microenvironment: can we distinguish reality from illusion? Neuro Oncol. Jan 30:noae019. doi: 10.1093/neuonc/noae019. PMID: 38290471
11) Ghosh S, **Rothlin CV**. (2024) Feeding the wrath with myelin. Trends Immunol. 2024 Oct;45(10):729-731. doi: 10.1016/j.it.2024.09.004. Epub 2024 Sep 27. PMID: 39341708

Patents

"Use of TAM Receptor Inhibitors as Immunoenhancers", Inventors: Carla V. Rothlin and Greg E. Lemke. Licensed to Kolltan Pharmaceuticals, New Haven, Connecticut.

"TAM Activators and Ligands to Inhibit Inflammation", Inventors: Carla V. Rothlin and Greg E. Lemke. Licensed to Kolltan Pharmaceuticals, New Haven, Connecticut.